PATENT CLAIM ANALYSIS

Application Number: 16206953
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["424", "452000"]

Abstract:
Methods for individualized therapy of arthritic pain using a non-steroidal anti-inflammatory drug (COX-2 inhibitor). Said methods comprise basing COX-2 inhibitor dose on each patient's pharmacokinetic response to said COX-2 inhibitor.

Claim (Index 1):
A method for treating pain in a patient, comprising:\n a. administering to the patient a first formulation of celecoxib and hydrochlorothiazide in a fixed dose combination; b. taking a patient plasma or serum sample and measuring, using a bioassay, the concentration of the celecoxib in the patient's plasma or serum at a plurality of time points after the first administration of celecoxib and hydrochlorothiazide; c. using a computer program, calculating an AUC value using the patient's celecoxib concentration and time data points; d. using a computer program, comparing the patient's celecoxib AUC values to a predetermined range of celecoxib AUC values and if one or more of the patient's celecoxib AUC values fall outside the predetermined range, designing a new celecoxib and hydrochlorothiazide formulation, where the dose of the celecoxib and/or hydrochlorothiazide, is different from that of the first formulation; e. administering the new celecoxib and hydrochlorothiazide formulation to the patient; f. repeating steps b-e, until the AUC value of the celecoxib is within the predetermined range; g. administering the celecoxib and hydrochlorothiazide to the patient for a period time sufficient to treat the pain, but not less than sixty (60) days; and h. if pain control is adequate, toxicity is tolerable, and the treatment reduces the incidence of edema in the patient administered celecoxib and hydrochlorothiazide as compared to a patient administered celecoxib alone, then maintaining the patient on celecoxib and hydrochlorothiazide for a period of not less than sixty (60) days at a frequency of administration that maintains the AUC identified in step f; wherein, the treatment reduces the incidence of edema in the patient administered celecoxib and hydrochlorothiazide as compared to a patient administered celecoxib alone by at least about 17%.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12426530', '14619634', '15589158', '16054578', '10158216']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7263053931603107
- 35 USC 102 Novelty (BERT): 0.509587053819637
- Combined Prediction Score: 0.7046335592262434
- Mean Citation Score: 231.748518
- Max Citation Score: 249.41182
- Similarity Product: 151.1454078628385

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test